Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, gives his expert perspective on treatment advances in urothelial cancers.
Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, summarizes a panel discussion on this important topic.
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499).
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for treating clear cell cancer.
Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer in a cohort of American doctors (Abstract 306).
Fred Saad, MD, of the University of Montreal, summarizes in French his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease.
